Kite Reports Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/16/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints investors, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
Kite Pharma (KITE) PT Raised to $120 at Canaccord Genuity
August 8, 2017 12:51 PM EDTCanaccord Genuity raised its price target on Kite Pharma (NASDAQ: KITE) to $120.00 (from $115.00) while maintaining a Buy rating.
Analyst John Newman with the coverage.
... MoreKite Pharma (KITE) Post Smaller Q2 Loss on Higher Revs
August 8, 2017 8:01 AM EDTKite Pharma (NASDAQ: KITE) reported Q2 EPS of ($1.50), $0.48 better than the analyst estimate of ($1.98). Revenue for the quarter came in at $10.1 million versus the consensus estimate of $9.59 million.
"We've continued to make significant progress on key clinical and commercial milestones in the... More
